Curcumin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Curcumin
Accession Number
DB11672
Type
Small Molecule
Groups
Investigational
Description

Curcumin is under investigation for the treatment and supportive care of Mucositis, Rectal Cancer, Prostate Cancer, Chronic Schizophrenia, and Mild Cognitive Impairment (MCI), among others. Curcumin has been investigated for the treatment and supportive care of Proteinuria, Breast Cancer, Multiple Myeloma, Major Depression, and Non Small Cell Lung Cancer, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
E 100 / E-100 / E100 / INS NO. 100(I) / INS-100(I) / NSC-32982
Product Ingredients
IngredientUNIICASInChI Key
Curcumin Sulfate160DHE331M 339286-19-0NEJVQQBBTRFOHB-FCXRPNKRSA-N
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
IT942ZTH98
CAS number
458-37-7
Weight
Average: 368.3799
Monoisotopic: 368.125988372
Chemical Formula
C21H20O6
InChI Key
VFLDPWHFBUODDF-FCXRPNKRSA-N
InChI
InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
IUPAC Name
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
SMILES
COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
UVitamin D3 receptorNot AvailableHuman
UMultidrug resistance-associated protein 5
inhibitor
Human
UCarbonyl reductase [NADPH] 1Not AvailableHuman
UGlutathione S-transferase PNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Curcumin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Curcumin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Curcumin is combined with 5-androstenedione.Experimental, Illicit
AbciximabCurcumin may increase the anticoagulant activities of Abciximab.Approved
AcebutololCurcumin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Curcumin.Approved
AcenocoumarolCurcumin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Curcumin.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Curcumin.Approved, Vet Approved
AclarubicinCurcumin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Curcumin.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Curcumin is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Curcumin is combined with Alendronic acid.Approved
AliskirenCurcumin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololCurcumin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Curcumin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Curcumin is combined with Amcinonide.Approved
AmikacinCurcumin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCurcumin may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinCurcumin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodCurcumin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Curcumin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Curcumin is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Curcumin is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Curcumin is combined with Anisodamine.Investigational
annamycinCurcumin may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Curcumin.Approved
Antithrombin III humanCurcumin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCurcumin may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Curcumin is combined with Acetovanillone.Investigational
ApramycinCurcumin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Curcumin.Approved, Investigational
ArbekacinCurcumin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinCurcumin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanCurcumin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololCurcumin may decrease the antihypertensive activities of Arotinolol.Approved
AtenololCurcumin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Curcumin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Curcumin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Curcumin.Approved
BalsalazideCurcumin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminCurcumin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Curcumin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCurcumin may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Curcumin.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Curcumin.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Curcumin.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Curcumin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Betamethasone.Approved, Vet Approved
BetaxololCurcumin may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Curcumin is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Curcumin.Approved, Investigational
BevantololCurcumin may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Curcumin.Approved, Investigational
BisoprololCurcumin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCurcumin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCurcumin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Curcumin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Curcumin is combined with Bucillamine.Investigational
BucindololCurcumin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Curcumin is combined with Budesonide.Approved
BufuralolCurcumin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideCurcumin may decrease the diuretic activities of Bumetanide.Approved
BupranololCurcumin may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Curcumin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Curcumin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Curcumin.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Curcumin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Curcumin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Curcumin.Approved, Vet Approved, Withdrawn
CarteololCurcumin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCurcumin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Curcumin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Celecoxib.Approved, Investigational
CeliprololCurcumin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinCurcumin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Curcumin.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Curcumin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Curcumin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Curcumin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Curcumin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Curcumin.Approved
CinoxacinCurcumin may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinCurcumin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidCurcumin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Curcumin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Curcumin is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Curcumin is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Curcumin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Curcumin.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Curcumin is combined with Cortisone acetate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Curcumin.Approved, Investigational
CyclosporineCurcumin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Curcumin.Investigational
Dabigatran etexilateCurcumin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinCurcumin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCurcumin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCurcumin may increase the anticoagulant activities of Ym150.Investigational
DaunorubicinCurcumin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Curcumin is combined with Deferasirox.Approved, Investigational
DesirudinCurcumin may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Curcumin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Curcumin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Curcumin.Approved
DextranCurcumin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Curcumin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Curcumin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Curcumin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Curcumin.Approved, Vet Approved
DicoumarolCurcumin may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Curcumin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Curcumin is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Curcumin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Curcumin.Approved
DihydrostreptomycinCurcumin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Curcumin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Curcumin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Curcumin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Curcumin.Approved, Investigational
DoxorubicinCurcumin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneCurcumin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Curcumin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Curcumin is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Curcumin is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Curcumin is combined with Ebselen.Investigational
Edetic AcidCurcumin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCurcumin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Curcumin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Curcumin.Approved
EnoxacinCurcumin may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinCurcumin may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Curcumin.Approved
EpirubicinCurcumin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCurcumin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Curcumin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Curcumin.Approved
EquileninThe risk or severity of adverse effects can be increased when Curcumin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Curcumin is combined with Equilin.Approved
EsmololCurcumin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Curcumin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Curcumin is combined with Estrone sulfate.Approved
Etacrynic acidCurcumin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Curcumin.Approved, Investigational
Ethyl biscoumacetateCurcumin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Curcumin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Curcumin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Curcumin.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Curcumin.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Curcumin.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Curcumin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Curcumin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Curcumin.Vet Approved
FleroxacinCurcumin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Curcumin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Curcumin is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Fludrocortisone.Approved
FluindioneCurcumin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCurcumin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Curcumin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Curcumin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Curcumin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Curcumin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Curcumin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Curcumin.Approved, Nutraceutical, Vet Approved
FondaparinuxCurcumin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCurcumin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Curcumin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Curcumin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Curcumin.Approved
FramycetinCurcumin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCurcumin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateCurcumin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCurcumin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCurcumin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Curcumin.Approved, Withdrawn
GemifloxacinCurcumin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCurcumin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCurcumin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACurcumin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinCurcumin may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Curcumin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Curcumin is combined with HE3286.Investigational
HeparinCurcumin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Curcumin is combined with Higenamine.Investigational
HydralazineCurcumin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Curcumin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Curcumin.Approved
Hygromycin BCurcumin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Curcumin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Curcumin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Curcumin.Approved
IdarubicinCurcumin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxCurcumin may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Curcumin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Curcumin.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Curcumin.Approved
IndenololCurcumin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Curcumin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Curcumin.Withdrawn
INNO-206Curcumin may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Curcumin.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Curcumin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Curcumin is combined with Istaroxime.Investigational
KanamycinCurcumin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Curcumin.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Curcumin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Curcumin.Approved
LabetalolCurcumin may decrease the antihypertensive activities of Labetalol.Approved
LandiololCurcumin may decrease the antihypertensive activities of Aop200704.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Curcumin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Curcumin.Approved, Investigational
LepirudinCurcumin may increase the anticoagulant activities of Lepirudin.Approved
LevobunololCurcumin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCurcumin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Curcumin.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Curcumin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Curcumin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Curcumin.Approved
LomefloxacinCurcumin may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Curcumin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Curcumin.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Curcumin.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Curcumin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Curcumin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Curcumin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Curcumin.Approved
ME-609The risk or severity of adverse effects can be increased when Curcumin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Curcumin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Curcumin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Curcumin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Curcumin.Approved, Vet Approved
MesalazineCurcumin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Curcumin.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Curcumin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Curcumin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololCurcumin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin.Approved
MetoprololCurcumin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideCurcumin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Curcumin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Curcumin is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Curcumin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Curcumin.Approved
MoxifloxacinCurcumin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Curcumin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Curcumin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Nabumetone.Approved
NadololCurcumin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCurcumin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatCurcumin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Curcumin.Approved
Nalidixic AcidCurcumin may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Curcumin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Curcumin is combined with NCX 1022.Investigational
NeamineCurcumin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinCurcumin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCurcumin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Curcumin.Approved
NetilmicinCurcumin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Curcumin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Curcumin.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Curcumin is combined with Nitroaspirin.Investigational
NorfloxacinCurcumin may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinCurcumin may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Curcumin.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Curcumin is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Curcumin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Curcumin.Approved
OlsalazineCurcumin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Curcumin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Curcumin.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Curcumin.Vet Approved
OtamixabanCurcumin may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Curcumin.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Curcumin.Approved
OxprenololCurcumin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Curcumin.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Curcumin.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Curcumin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Parecoxib.Approved
ParomomycinCurcumin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinCurcumin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCurcumin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCurcumin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateCurcumin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Curcumin.Approved
PhenindioneCurcumin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonCurcumin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Curcumin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Curcumin.Approved, Investigational
PindololCurcumin may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinCurcumin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCurcumin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Curcumin.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Curcumin.Approved, Investigational
PlicamycinCurcumin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Curcumin.Approved
PractololCurcumin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Curcumin.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Curcumin is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Curcumin is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Curcumin can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Curcumin.Approved
PropranololCurcumin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Curcumin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Curcumin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Curcumin.Vet Approved
Protein CCurcumin may increase the anticoagulant activities of Protein C.Approved
Protein S humanCurcumin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCurcumin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCurcumin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Curcumin.Investigational
PuromycinCurcumin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Curcumin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Curcumin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Curcumin.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Curcumin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Curcumin.Experimental, Investigational
ReviparinCurcumin may increase the anticoagulant activities of Reviparin.Approved
RibostamycinCurcumin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Curcumin is combined with Risedronate.Approved, Investigational
RivaroxabanCurcumin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinCurcumin may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Curcumin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Curcumin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Curcumin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Curcumin.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Curcumin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Curcumin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Curcumin.Approved
SisomicinCurcumin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolCurcumin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCurcumin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCurcumin may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinCurcumin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Curcumin.Approved
SpironolactoneCurcumin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Curcumin.Investigational
StreptomycinCurcumin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCurcumin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineCurcumin may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Curcumin.Approved
SulodexideCurcumin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Curcumin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Curcumin.Approved, Withdrawn
TacrolimusCurcumin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Curcumin.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Curcumin.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Curcumin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Curcumin is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Curcumin is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Curcumin.Approved, Investigational
TemafloxacinCurcumin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Curcumin.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Curcumin is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Curcumin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Curcumin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Curcumin.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Curcumin.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Curcumin is combined with Tiludronate.Approved, Vet Approved
TimololCurcumin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Curcumin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Curcumin is combined with Tixocortol.Approved
TobramycinCurcumin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Curcumin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Curcumin.Approved
TorasemideCurcumin may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Curcumin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Curcumin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Curcumin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Curcumin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Curcumin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Curcumin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCurcumin may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Curcumin.Approved, Vet Approved
TrovafloxacinCurcumin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Curcumin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Curcumin is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinCurcumin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Curcumin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Curcumin.Approved
WarfarinCurcumin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCurcumin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Curcumin.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Curcumin.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Curcumin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Curcumin.Withdrawn
ZorubicinCurcumin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB02269
ChemSpider
839564
ChEBI
3962
ChEMBL
CHEMBL140
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentCervical Intraepithelial Neoplasia (CIN)1
0RecruitingTreatmentMetastatic Colon Cancer1
0Unknown StatusTreatmentRheumatoid Arthritis1
1CompletedNot AvailableColorectal Cancers1
1CompletedOtherComparative Multidose Pharmacokinetics1
1CompletedTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
1CompletedTreatmentDentist-Patient Relations1
1CompletedTreatmentUterine Cervical Dysplasia1
1RecruitingSupportive CareBladder Spasms / Neoplasms, Malignant / Pain / Urination urgency of1
1Unknown StatusTreatmentHyperprolactinoma1
1WithdrawnTreatmentAdvanced Cancers1
1, 2CompletedTreatmentAlzheimer's Disease (AD)1
1, 2CompletedTreatmentHealthy Volunteers (Middle-aged Smokers)1
1, 2RecruitingTreatmentGulf War Syndrome1
1, 2RecruitingTreatmentMucositis1
1, 2RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1
1, 2Unknown StatusTreatmentCognition / Psychosis / Schizophrenic Disorders1
1, 2WithdrawnSupportive CareNon-Small-Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingSupportive CareAge-associated Cognitive Impairment / Mild Cognitive Impairment (MCI)1
2Active Not RecruitingSupportive CareProstate Cancer1
2Active Not RecruitingTreatmentProstate Cancer Metastatic Castration Resistant1
2Active Not RecruitingTreatmentRectal Carcinoma1
2CompletedPreventionHealthy, no Evidence of Disease / Tobacco Use Disorders1
2CompletedSupportive CareCarcinoma, Breast / Pain / Radiation-Induced Dermatitis / Stage 0 Breast Cancer1
2CompletedTreatmentAdenocarcinomas / Neoplasms, Pancreatic1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentFamilial Adenomatous Polyposis (FAP)1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentOral Lichen Planus1
2Not Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Cognitive Decline1
2RecruitingPreventionChronic Atrophic Gastritis (CAG) / Intestinal Metaplasia of Gastric Mucosa1
2RecruitingPreventionMild Cognitive Impairment (MCI)1
2RecruitingTreatmentAdvanced Breast Cancer / Metastatic Breast Cancer (MBC)1
2RecruitingTreatmentBipolar Disorder (BD)1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentProstate Cancer1
2WithdrawnNot AvailableFamilial Adenomatous Polyposis (FAP)1
2WithdrawnTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2, 3CompletedPreventionAbdominal Aortic Aneurysms (AAA) / Acute Kidney Injury (AKI)1
2, 3CompletedPreventionRadiation-Induced Dermatitis1
2, 3Not Yet RecruitingPreventionCognitive Function / Older Adults / Physical Function1
3CompletedTreatmentOptic Atrophy, Hereditary, Leber1
3CompletedTreatmentProteinuria1
3CompletedTreatmentSynovitis of osteoarthritis1
3RecruitingTreatmentCrohn's Disease (CD)1
3Unknown StatusNot AvailableMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentColon Neoplasms1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4RecruitingTreatmentChronic Schizophrenia1
4RecruitingTreatmentPolycystic Kidney, Autosomal Dominant1
4Unknown StatusPreventionCardiovascular Risks / Insulin Resistance / Pre-Diabetic / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentCardiovascular Abnormalities / Type 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
Not AvailableCompletedPreventionChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableTerminatedPreventionAberrant Crypt Foci1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00575 mg/mLALOGPS
logP3.62ALOGPS
logP4.12ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.06ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity103.81 m3·mol-1ChemAxon
Polarizability38.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0fbc-0923000000-107f42bbc825be91449b
LC-MS/MS Spectrum - LC-ESI-ITTOF , negativeLC-MS/MSsplash10-0600-0920000000-c006d38848959c621ec5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0982000000-2c508f0e4a39ae290728
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00di-0950000000-af821cd7589af1e24d16
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0fk9-0981000000-e4da18f81a545b08874b
LC-MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-2920000000-3c3aa8613bf16651cdf5
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as curcuminoids. These are aromatic compounds containing a curcumin moiety, which is composed of two aryl buten-2-one (feruloyl) chromophores joined by a methylene group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Diarylheptanoids
Sub Class
Linear diarylheptanoids
Direct Parent
Curcuminoids
Alternative Parents
Hydroxycinnamic acids and derivatives / Methoxyphenols / Styrenes / Phenoxy compounds / Methoxybenzenes / Anisoles / Beta-diketones / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Enones
show 4 more
Substituents
Curcumin / Hydroxycinnamic acid or derivatives / Methoxyphenol / Anisole / Phenoxy compound / Phenol ether / Styrene / Methoxybenzene / Phenol / 1,3-diketone
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, enone, polyphenol, beta-diketone, diarylheptanoid (CHEBI:3962 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M: Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 2005 Feb 23;53(4):959-63. [PubMed:15713005 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
VDR
Uniprot ID
P11473
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
References
  1. Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, Hernandez Z, Haussler CA, Haussler MR, Jurutka PW: Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem. 2010 Dec;21(12):1153-61. doi: 10.1016/j.jnutbio.2009.09.012. Epub 2010 Feb 12. [PubMed:20153625 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Prehm P: Curcumin analogue identified as hyaluronan export inhibitor by virtual docking to the ABC transporter MRP5. Food Chem Toxicol. 2013 Dec;62:76-81. doi: 10.1016/j.fct.2013.08.028. Epub 2013 Aug 24. [PubMed:23978416 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin-e2 9-reductase activity
Specific Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
Gene Name
CBR1
Uniprot ID
P16152
Uniprot Name
Carbonyl reductase [NADPH] 1
Molecular Weight
30374.73 Da
References
  1. Hintzpeter J, Hornung J, Ebert B, Martin HJ, Maser E: Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1. Chem Biol Interact. 2015 Jun 5;234:162-8. doi: 10.1016/j.cbi.2014.12.019. Epub 2014 Dec 22. [PubMed:25541467 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521 ]
Drug created on October 20, 2016 14:38 / Updated on September 01, 2017 12:11